This view is based upon the frequency of VHL mutations, found in >90% of ccRCC which led to HIF2α stabilisation, and the HIF2α functional in vitro investigations using cell lines and murine models of ccRCC which have limitations [21]. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.